BioSpace News Archive

Hillstream BioPharma, Inc. today announced that Randy Milby, Founder and Chief Executive Officer will present in-person and host one-on-one meetings with investors at the following conferences.

Hyperfine, Inc. announced that it has named medical device industry veteran Maria Sainz as President and Chief Executive Officer of Hyperfine, effective October 24, 2022.

Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”,) announced today the United States Patent and Trademark Office (USPTO) has issued the Company a new patent (patent # 11446428) titled, “Cleaning Method for Prepless Colonoscopy.”

Sorrento Therapeutics, Inc. announced that Dr. Mike A. Royal, Chief Medical Officer, will participate in an upcoming Key Opinion Leader Panel Discussion that will focus on the great unmet need in non-small cell lung cancer and the potential of abivertinib, a novel, third-generation, EGFR/BTK inhibitor.

Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that the Company will present one-year safety and efficacy results from its HOPE-2 open-label extension study with lead asset CAP-1002 for treating Duchenne muscular dystrophy (DMD).

Amgen announced the opening of a new research and development site in San Francisco’s Oyster Point, continuing the company’s nearly two-decade presence in the region.

CurvaFix, Inc. announced participation in the Industry Sessions of the Orthopaedic Trauma Association 38th Annual Meeting, Oct. 12-15 in Tampa, Fl, highlighting the expanding use of the CurvaFix® IM Implant by industry-leading surgeons for both fragility and high-impact fractures of the pelvis.

Owlet, Inc. (NYSE: OWLT) (the “Company”) announces that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (“FDA”) for a new prescription monitoring device for infants.

Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that it will host a key opinion leader (KOL) webinar highlighting oral APX3330, its lead drug candidate for diabetic retinopathy (DR) and diabetic macular edema (DME), on Friday, October 14, 2022 at 11AM to 12:30PM Eastern Time.

Simcere Pharmaceutical Group（2096.HK), an innovation and R&D-driven pharmaceutical company, and Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on skin health; announced today that they have entered into an exclusive licensing agreement for Simcere’s IL-2 mutant fusion protein (IL-2 mu-Fc) autoimmune drug candidate, SIM0278.